Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hong

Showing results (101-110 of 272) with videos related to

Pageof 28
Sort By:
Cancer|January 29, 2010
Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumorsFaye M Johnson, Shruti Agrawal, Howard Burris, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2009
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experienceApostolia Maria Tsimberidou, Christos Vaklavas, Sijin Wen, et al.
Journal of Computer Assisted Tomography|December 1, 2017
Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver TumorsPayel Ghosh, Adam G Chandler, Brian P Hobbs, et al.
Oncotarget|November 27, 2014
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experienceMing-Mo Hou, Xiaochun Liu, Jennifer Wheler, et al.
Investigational New Drugs|December 6, 2013
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignanciesSiqing Fu, Ming-Mo Hou, Jennifer Wheler, et al.
Oncotarget|June 15, 2013
Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analysesJennifer Wheler, David Hong, Stephen G Swisher, et al.
Investigational New Drugs|March 5, 2025
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphomaMelissa Johnson, David Hong, Irene Braña, et al.
Cancer|August 25, 2005
Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinomaDavid Hong, Simon Lunagomez, E Edmund Kim, et al.
Journal of Cancer|February 18, 2011
Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid TumorsAung Naing, James M Reuben, Luis H Camacho, et al.
Cancer|June 22, 2010
A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liverApostolia M Tsimberidou, Siqing Fu, Chaan Ng, et al.
Pageof 28

Showing results (101-110 of 272) with videos related to

Sort By:
Pageof 28
Cancer|January 29, 2010
Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumorsFaye M Johnson, Shruti Agrawal, Howard Burris, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2009
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experienceApostolia Maria Tsimberidou, Christos Vaklavas, Sijin Wen, et al.
Journal of Computer Assisted Tomography|December 1, 2017
Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver TumorsPayel Ghosh, Adam G Chandler, Brian P Hobbs, et al.
Oncotarget|November 27, 2014
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experienceMing-Mo Hou, Xiaochun Liu, Jennifer Wheler, et al.
Investigational New Drugs|December 6, 2013
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignanciesSiqing Fu, Ming-Mo Hou, Jennifer Wheler, et al.
Oncotarget|June 15, 2013
Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analysesJennifer Wheler, David Hong, Stephen G Swisher, et al.
Investigational New Drugs|March 5, 2025
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphomaMelissa Johnson, David Hong, Irene Braña, et al.
Cancer|August 25, 2005
Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinomaDavid Hong, Simon Lunagomez, E Edmund Kim, et al.
Journal of Cancer|February 18, 2011
Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid TumorsAung Naing, James M Reuben, Luis H Camacho, et al.
Cancer|June 22, 2010
A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liverApostolia M Tsimberidou, Siqing Fu, Chaan Ng, et al.
Pageof 28